Drug Profile
Research programme: anti-infective monoclonal antibody therapeutics - Regeneron/BARDA
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Anti-infectives; Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Infections; Influenza virus infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 22 Aug 2023 Regeneron Pharmaceuticals and Biomedical Advanced Research and Development Authority agreed to co-develop COVID-19 monoclonal antibody therapy for SARS-CoV-2 infection
- 22 Aug 2023 Regeneron pharmaceuticals plans a clinical trial for SARS-CoV-2 infections in 2023